TheraVet SA

Equities

ALVET

BE0974387194

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 11:18:58 2024-07-12 am EDT			5-day change	1st Jan Change
0.371 ^EUR	-2.37%		-18.46%	-74.41%

May. 21	TheraVet SA Announces Early Completion of Patient Recruitment of the Visco-VET Clinical Study	CI
May. 07	FOMO is Back

TheraVet SA Reports Earnings Results for the Half Year Ended June 30, 2023

September 06, 2023 at 01:30 am EDT

TheraVet SA reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was EUR 0.610153 million compared to EUR 0.912797 million a year ago. Net loss was EUR 0.905157 million compared to EUR 1.18 million a year ago.

Latest news about TheraVet SA

TheraVet SA Announces Early Completion of Patient Recruitment of the Visco-VET Clinical Study	May. 21	CI
FOMO is Back	May. 07
TheraVet SA Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 23	CI
TheraVet SA Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 22	CI
TheraVet SA Announces the Launch of BIOCERA-VET Equine	Mar. 13	CI
TheraVet’s Veterinary Medicinal Product Gets Patents in Europe, Singapore, Israel	Jan. 30	MT
Global markets live: Charles Schwab, Apple, Spirit Airlines, BP, Visa...	Jan. 17
TheraVet SA Announces Commercial Launch of Biocera-VET in Germany	Jan. 17	CI
Global markets live: Boeing, GSK, Hays, Shell, Eli Lilly...	Jan. 09
TheraVet Announces Agreement with Alcyon Italia for the Distribution of BIOCERA-VET® Product Line in Italy	Jan. 09	CI
TheraVet: positive feedback in canine osteosarcoma	Jan. 04	CF
TheraVet launches osteosarcoma study	Nov. 23	CF
TheraVet SA Announces Launch of Biocera-Vet Canine Osteosarcoma Study Conducted by the University of Florida	Nov. 23	CI
TheraVet Sets Up EUR3 Million Equity-linked Funding Facility	Nov. 21	MT
TheraVet SA announced that it has received ?0.2 million in funding	Nov. 19	CI
Vet Biotech TheraVet Names CFO	23-10-25	MT
TheraVet Appoints Rodolphe Lebrun as Chief Financial Officer	23-10-25	CI
TheraVet Recruits Patients for Study on Bone Substitute Use in Dog Revision Surgery	23-09-27	MT
TheraVet SA Announces Patient Recruitment Phase Successfully Completed in Biocera-Vet Fracture Revision Surgery Study in Toy Dogs	23-09-27	CI
TheraVet: financing secured until mid-2024	23-09-06	CF
TheraVet SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-06	CI
TheraVet: growing interest in canine osteosarcoma	23-06-15	CF
TheraVet: new commercial launch, share price rises	23-05-31	CF
TheraVet SA Announces the Commercial Launch of A Local and Sustained Antibiotic Releasing Bone Substitute	23-05-31	CI
TheraVet SA Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-25	CI

Chart TheraVet SA

Duration

Period

More charts

Company Profile

TheraVet SA is specialized in the development of pharmaceutical products for the treatment of osteoarticular diseases in pets. At the end of 2023, the company had a portfolio of 2 products in the clinical development phase: Visco-Vet for the treatment of limping associated with osteoarthritis in dogs and Biocera-Vet for osseointegration and bone remodeling.

Sector

Biotechnology & Medical Research

Calendar

2024-09-12 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
THERAVET SA	-74.41%	1.3M
VERTEX PHARMACEUTICALS INCORPORATED	+20.12%	126B
REGENERON PHARMACEUTICALS, INC.	+25.25%	119B
ARGENX SE	+25.56%	27.95B
BIONTECH SE	-19.51%	20.5B
GENMAB A/S	-14.36%	17.12B
BEIGENE, LTD.	-15.63%	16.1B
WUXI APPTEC CO., LTD.	-46.67%	14.97B
NEUROCRINE BIOSCIENCES, INC.	+11.89%	14.84B
SAREPTA THERAPEUTICS, INC.	+57.74%	14.38B

Bio Therapeutic Drugs